top of page

Pharmacological Treatments: Incretin Therapies

GLP-1 agonists and DPP4 inhibitors

As well as exercise and a healthy diet, Type 2 Diabetes Mellitus (T2DM) can be treated by insulin, sulfonylurea and metformin.


However, T2DM can also be effectively treated by the incretin therapies:


GLP-1 agonists and DPP4 inhibitors

​

The purpose of the resources below is to explain the beneficial and therapeutic effects of incretin therapies.

​

Image by Myriam Zilles
Pharmacological Treatment: Incretin Therapies: About
Final GLP-1 agonists vs Type 2 Diabetes
Pharmacological Treatment: Incretin Therapies: Image

Video on GLP-1 agonists

This video should hopefully give you a clear idea about what GLP-1 agonists are.
Sit back and enjoy!

Pharmacological Treatment: Incretin Therapies: HTML Embed
Final DPP4 inhibitors vs Type 2 Diabetes
Pharmacological Treatment: Incretin Therapies: Image

Video on DPP4 inhibitors

This video should hopefully give you a clear explanation of the beneficial effects of DPP4 inhibitors.
Sit back and enjoy!

Pharmacological Treatment: Incretin Therapies: HTML Embed

Extra information on Type 2 Diabetes, Incretin Therapies and More Treatments

Useful website links and references:

​

https://www.nhs.uk/medicines/metformin

https://www.nhs.uk/medicines/sitagliptin

​

www.nhs.uk/medicines/saxagliptin

​

mytype1diabetes.nhs.uk/resources/internal/what-are-glp-1-analogues-incretin-mimetics

​

www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493

​

www.diabetes.co.uk/diabetes-medication/incretin-mimetics.html

​

www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/tablets-and-medication/incretin-mimetics

​

www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/tablets-and-medication/dpp-4-inhibitors-gliptins

​

Baggio, L.L. and Drucker, D.J. (2007). Biology of Incretins: GLP-1 and GIP. Gastroenterology, 132(), pp.2131–2157.

​

Greiner, T.U. and Bäckhed, F. (2016). Microbial regulation of GLP-1 and L-cell biology. Molecular Metabolism, 5(), pp.753–758.

​

Patti, A.M., Nikolic, D., Magan-Fernandez, A., Giglio, R.V., Castellino, G., Chianetta, R., Citarrella, R.,

Corrado, E., Provenzano, F., Provenzano, V., Montalto, G., Rizvi, A.A. and Rizzo, M. (2019).

Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intimamedia

thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Research

and Clinical Practice , 149, pp.163–169.

​

Szayna, M., Doyle, M.E., Betkey, J.A., Holloway, H.W., Spencer, R.G.S., Greig, N.H. and Egan, J.M.

(2000). Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

Endocrinology, 141, pp.1936–1941.


​

​

Pharmacological Treatment: Incretin Therapies: Text

©2021 by Manchester Diabetes. Proudly created with Wix.com

bottom of page